Critical Safety Warning: Lesuride Does Not Exist as a Prokinetic Agent
There is no FDA-approved or medically recognized drug called "lesuride" for prokinetic use, and the 25 mg IV dose mentioned in your question does not correspond to any established prokinetic medication.
Important Clarification
The evidence provided contains information about leuprolide acetate (a GnRH agonist used for hormone-dependent conditions) 1, which is completely unrelated to prokinetic therapy. This appears to be a critical medication name confusion that must be addressed immediately.
If You Meant Cisapride
Cisapride was withdrawn from most markets worldwide due to serious cardiac arrhythmias and sudden death, particularly when combined with CYP3A4 inhibitors or in patients with QT prolongation 2. It is no longer available for routine clinical use in most countries.
Historical Cisapride Dosing (For Reference Only)
When cisapride was available, IV administration used:
The drug showed prokinetic effects on gastric emptying and lower esophageal sphincter pressure 3, 4, but cardiac safety concerns led to its withdrawal 2.
Current Evidence-Based Prokinetic Recommendations
For gastroparesis requiring prokinetic therapy, use metoclopramide or erythromycin as first-line agents 7:
Metoclopramide
- Start 5 mg PO three times daily before meals
- Titrate gradually based on symptom response
- Monitor for extrapyramidal side effects and tardive dyskinesia risk
- FDA black box warning for chronic use >12 weeks
Erythromycin
- 40-250 mg daily before meals
- Higher doses associated with more adverse effects and tachyphylaxis
- Evaluate response at 4-8 weeks
Critical Action Required
Stop and verify the actual medication name and intended use before proceeding. If this is for gastroparesis or another motility disorder, consult current guidelines 7 and use established prokinetic agents with known safety profiles rather than attempting to use a non-existent or incorrectly named medication.